Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 February 11, 2022 at 12:00 PM UTC
Internal link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen January 04, 2022 at 12:00 PM UTC